-
ACTG REPRIEVE STUDY EARLY STOP ANNOUNCEMENT
Apr 14, 2023
-
Mar 28, 2023
-
ACTG ANNOUNCES PUBLICATION OF PIVOTAL HEPATITIS C STUDY IN CLINICAL INFECTIOUS DISEASES
Mar 23, 2023
-
2023 HYBRID ANNUAL ACTG NETWORK MEETING
Feb 16, 2023
-
ACTG TO MAKE 29 PRESENTATIONS AT CROI 2023
Feb 14, 2023
-
REPRIEVE TRIAL CARDIOVASCULAR DISEASE RISK AND PREVENTION IN INFLAMMATION: THE REPRIEVE TRIAL IN HIV
Jan 11, 2023
-
A MESSAGE FROM LEADERSHIP - CLUB Q STATEMENT OF SOLIDARITY
Nov 23, 2022
-
Oct 20, 2022
-
ACTG MAKES THREE COVID-19-FOCUSED PRESENTATIONS AT IDWEEK 2022
Oct 20, 2022
-
ACTG ANNOUNCES RESULTS FROM INVESTIGATIONAL INHALED COVID-19 TREATMENT IN ACTIV-2 PHASE 2 STUDY
Oct 04, 2022
-
IDSA MEDIA BRIEFING ON MONKEYPOX TREATMENT TRIALS
Oct 03, 2022
-
ACTG ANNOUNCES LAUNCH OF TRIAL EVALUATING MONKEYPOX TREATMENT
Sep 09, 2022
Press Releases & Announcements